Pradžia › B ląstelių leukemija › Kalifornija
B ląstelių leukemija klinikiniai tyrimai Kalifornija
7 tyrimai dėl B ląstelių leukemija ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT06542250Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- University of California San Diego Moores Cancer Center ( Site 2717), La Jolla
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-24 · NCT04728893Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, La Jolla
Renkami dalyviai3 fazė
Amžius nuo 18 iki 18 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07509151Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
Renkami dalyviai2 fazė
Amžius nuo 7 iki 25 · Visoms lytims · Atnaujinta 2026-08-19 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-17 · NCT05254743The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- ir dar 1
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- City of Hope, Duarte
- Stanford, Palo Alto
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.